Amgen cancer drug meets main goal in late-stage study
Aug 4 (Reuters) - Amgen Inc said its cancer drug significantly improved the length of time that patients lived with a type of blood cancer without the disease worsening.
Amgen's share rose 4.3 percent to $130.96 in premarket trading on Monday after the company released the interim data from a late-stage study.
The trial was testing the drug, Kyprolis, in combination with two other treatments, against those treatments alone in previously-treated patients with relapsed multiple myeloma. (Reporting by Natalie Grover in Bangalore; Editing by Savio D'Souza)